CO.DON

Executive Summary

CO.DON is a German biopharmaceutical company specializing in personalized cell therapies for the regeneration of joint cartilage defects, primarily through autologous chondrocyte transplantation. Founded in 1993 and headquartered in Berlin, the company has focused on preserving joints and enabling active living for patients with cartilage damage. In 2023, CO.DON was acquired by ReLive Biotechnology, a move aimed at strengthening the commercialization and development of its cell-based therapy platform. Despite the acquisition, CO.DON continues to operate under its own brand and maintains its expertise in tissue engineering and regenerative medicine. The company's current pipeline centers on its lead product, an autologous chondrocyte implant for knee cartilage defects. While CO.DON has a longstanding presence in the cell therapy space, its market reach remains limited to select European countries, with regulatory approvals in Germany and potentially other EU member states. As a private entity, financial details and specific development milestones are not publicly disclosed. However, potential near-term catalysts include expanded regulatory approvals across Europe, strategic partnerships to leverage the ReLife network, and initiation of clinical studies for new indications such as hip or ankle cartilage repair. The company's success depends on navigating the complex regulatory landscape for personalized cell therapies and demonstrating clinical efficacy to gain broader reimbursement coverage.

Upcoming Catalysts (preview)

• H2 2026Regulatory approval for CO.DON implant in additional EU countries65% success
• 2027New clinical trial for hip or ankle cartilage repair40% success
• 2026-2027Partnership or licensing agreement with a major pharmaceutical company30% success